Phase

Philogen Announces Clinical Trial Collaboration with MSD

Retrieved on: 
Thursday, June 1, 2023

The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy™ in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in stage III and IV unresectable melanoma patients who previously failed treatment with checkpoint inhibitors

Key Points: 
  • The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy™ in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in stage III and IV unresectable melanoma patients who previously failed treatment with checkpoint inhibitors
    Siena, Italy, June 1st, 2023 - Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative medicines based on tumor-targeting antibodies and small molecule ligands, announces that it has entered into a Clinical Trial Collaboration and Supply Agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA).
  • Under the terms of the supply agreement, MSD provides their anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), to be evaluated in combination with Philogen's immunocytokines L19IL2, L19TNF, and Nidlegy™ in a randomized Phase II clinical trial.
  • Dario Neri, CEO and CSO of Philogen, commented: "KEYTRUDA® has shown impressive response rates and long-term benefits for a substantial number of patients with advanced melanoma.
  • Nidlegy™ is a registered trademark of Philogen S.p.A. of La Lizza 7, 53100 Siena, ITALY.

Sarah Cannon Research Institute to Present Latest Oncology Research Insights at 2023 ASCO® Annual Meeting

Retrieved on: 
Thursday, June 1, 2023

Sarah Cannon Research Institute (SCRI) announced that its network of research leaders have been selected to deliver insights through more than 135 abstracts and presentations at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting June 2-6, 2023.

Key Points: 
  • Sarah Cannon Research Institute (SCRI) announced that its network of research leaders have been selected to deliver insights through more than 135 abstracts and presentations at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting June 2-6, 2023.
  • In 2022, SCRI joined together with US Oncology Research as one company to transform oncology research and improve care in more than 24 states across the U.S. Operating as SCRI, the unified research network has over 1,300 physicians enrolling patients to more than 1,000 trials annually.
  • “The collaborations across SCRI’s expanded network are accelerating progress and serving more patients closer to where they live,” says Howard A.
  • “We are looking forward to this year’s Annual Meeting where we will be discussing the results of trials that are advancing therapies across a variety of cancers.”
    For a comprehensive list of abstracts and presentations, click here .

Ivonescimab Updated Data to be Featured at ASCO 2023

Retrieved on: 
Thursday, June 1, 2023

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
  • The poster with updated clinical data from Phase II clinical trials will be displayed on Sunday June 4 from 8:00 to 11:00am Central Time during the Lung Cancer – Non-Small Cell Metastatic Poster Session.
  • The poster provides updated data supporting promising anti-tumor activity of ivonescimab in first line advanced or metastatic NSCLC, while displaying that ivonescimab may have an acceptable safety profile in combination with platinum-doublet chemotherapy for patients with squamous or non-squamous advanced or metastatic NSCLC in this clinical study.
  • Over 750 patients have been treated with ivonescimab across multiple clinical studies in different indications in China and Australia.

RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial

Retrieved on: 
Thursday, June 1, 2023

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that the University of Texas (UT) Southwestern Medical Center is now enrolling pancreatic cancer patients in the open label, randomized Phase III TIGeR-PaC clinical trial.

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that the University of Texas (UT) Southwestern Medical Center is now enrolling pancreatic cancer patients in the open label, randomized Phase III TIGeR-PaC clinical trial.
  • “Pancreatic cancer is expected to be the second largest cause of cancer-related deaths before 2030*,” said Principal Investigator, Salwan Al Mutar, MD, MSc, Assistant Professor at UT Southwestern Medical Center.
  • This clinical trial is evaluating targeted, intra-arterial chemotherapy that is singularly focused on the tumor.”
    Ramtin Agah, M.D., RenovoRx’s Founder and Chief Medical Officer, commented, “UT Southwestern Medical Center is one of the world’s premier academic medical organizations, integrating research with exceptional clinical care.
  • UT Southwestern is the most recent clinical trial site to join the Phase III TIGeR-PaC study which continues enrolling patients at U.S. sites.

Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b

Retrieved on: 
Wednesday, May 31, 2023

These positive data support Coave’s preparations for a registrational trial with CTx-PDE6b in this indication.

Key Points: 
  • These positive data support Coave’s preparations for a registrational trial with CTx-PDE6b in this indication.
  • To date, CTx-PDE6b has been administered to 17 patients aged 18 years and older presenting an advanced form of PDE6b RP using two ascending doses.
  • The treatment was administered in the more affected eye while the other eye served as an untreated control.
  • “We are highly encouraged by the safety and efficacy data observed so far in patients who have been treated with CTx-PDE6b.

Immuron Initiates Recruitment of Travelan® Clinical Study

Retrieved on: 
Tuesday, May 30, 2023

MELBOURNE, Australia, May 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it has received approval from the U.S. Army Medical Research and Development Command (USAMRDC) Office of Human and Animal Research Oversight (OHRO) to proceed with the clinical trial to evaluate the efficacy of Travelan® to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli (ETEC).

Key Points: 
  • The study has also been granted Institutional Review Board (IRB) human ethics and US Food and Drug Administration (FDA) approvals (ASX announcement December 23, 2022).
  • Immuron is now proceeding with the planned clinical trial in the United States and has initiated recruitment.
  • The clinical study will be conducted by Pharmaron CPC at its FDA inspected Clinical Research Facility Inpatient Unit located in Baltimore, Maryland US.
  • This is one of four clinical trials Immuron has, or is soon to, initiate.

MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update

Retrieved on: 
Tuesday, May 30, 2023

YAVNE, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • Importantly, MediWound is now in a strong financial position, with over $57 million in cash.
  • This provides the company with ample resources to effectively execute its corporate initiatives and drive continuous innovation," stated Ofer Gonen, Chief Executive Officer of MediWound.
  • First Quarter 2023 Highlights and Recent Developments:
    The Company’s global Phase III clinical study for EscharEx is expected to begin in the fourth quarter of 2023.
  • The Company utilized $1.8 million to fund its operating activities in the first quarter of 2023.

WNDR Alpine Launches into Activewear with Phase Series Featuring 100% Petroleum-Free Wicking Finish

Retrieved on: 
Tuesday, May 30, 2023

WNDR® Alpine – the outdoor brand launched by the biotechnology company Checkerspot – is releasing the Phase Series, a high performance, low impact activewear line powered by ingredients derived from microalgae.

Key Points: 
  • WNDR® Alpine – the outdoor brand launched by the biotechnology company Checkerspot – is releasing the Phase Series, a high performance, low impact activewear line powered by ingredients derived from microalgae.
  • View the full release here: https://www.businesswire.com/news/home/20230530005188/en/
    The Phase Series: Built for your daily cadence of exertion and recovery (Photo: Kevin Kinghorn)
    The Phase Series builds upon WNDR Alpine’s successes creating award-winning backcountry skis and snowboards equipped with microalgae-derived high performance materials.
  • miDori® bioWick WA offers a 80% lower carbon footprint than a traditional wicking finish, while retaining competitive performance.
  • “I think of the Phase Series as an important part of our progression to bring biobased innovation to life through products that benefit the mountain athlete.

Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific A

Retrieved on: 
Friday, May 26, 2023

Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium commented, “This positive CHMP opinion for PYLCLARI® is an important step forward in our goal of redefining the experience of cancer through our trusted legacy in nuclear medicine.

Key Points: 
  • Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium commented, “This positive CHMP opinion for PYLCLARI® is an important step forward in our goal of redefining the experience of cancer through our trusted legacy in nuclear medicine.
  • Upon its approval, PYLCLARI® will become available across Europe to help patients along their prostate cancer journey.
  • We are very excited to bring PYLCLARI® to the market and contribute to improving the set of diagnostic tools available to better diagnose and monitor prostate cancer.
  • The CHMP’s positive opinion on PYLCLARI® will be referred to the European Commission, which will deliver a final decision in approximately two months.

Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting

Retrieved on: 
Friday, May 26, 2023

SYDNEY, AUSTRALIA, May 26, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces data from Part C of its TACTI-002 Phase II trial has been published in an abstract available on the 2023 American Society of Clinical Oncology’s (ASCO) Annual Meeting’s official website. A Trial in Progress abstract for the Phase II/III AIPAC-003 trial has also been published.

Key Points: 
  • A Trial in Progress abstract for the Phase II/III AIPAC-003 trial has also been published.
  • The TACTI-002 poster will contain more mature (longer follow up) and final data that is not part of the abstract and will be available on the Posters & Publication section of Immutep’s website after its presentation at ASCO.
  • Abstracts are available at ASCO.org .
  • Presenter: Dr. Nuhad K. Ibrahim, Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX